Eli Lilly and Company (NYSE:LLY) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. Eli Lilly and Company ...

Eli Lilly & Co. reports Q2 2025 results before the U.S. market opens on August 7. Analysts expect revenue of approximately ...

The Government has joined forces with the pharmaceutical giant that makes weight loss jab Mounjaro in a bid to tackle obesity ...

Eli Lilly’s GIP/GLP-1 dual receptor agonist Mounjaro (tirzepatide) has demonstrated cardiovascular protection in a late-stage ...

The mother's eyes turned yellow among other side effects while on Mounjaro, which had a devastating effect on her gallbladder ...

There has been a 27% YoY increase in sales of weight-loss drugs, especially after the launch of Mounjaro and Novo Nordisk's ...

Shares of Eli Lilly (NYSE: LLY), the pharmaceuticals giant and maker of the Mounjaro and Zepbound weight loss drugs, saw its ...

Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...

Eli Lilly's experimental GLP-1 pill shows promise in a Phase Three trial, helping users lose an average of 12% of body weight ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...

A mum who admitted that she has illegally put her 13-year-old child on Mounjaro weight loss jabs has spoken out on why she ...